Serum autoantibody to sideroflexin 3 as a novel tumor marker for oral squamous cell carcinoma

Proteomics - Clinical Applications

Volumn 2, Issue 4, 2008, Pages 517-527

  Murase, Ryuichi ^a   Abe, Yasuhito ^a   Takeuchi, Takashi ^a   Nabeta, Motowo ^a   Imai, Yoshinori ^a   Kamei, Yoshiaki ^a   Kagawa Miki, Lisa ^a   Ueda, Norifumi ^a   Sumida, Tomoki ^a   Hamakawa, Hiroyuki ^a   Kito, Katusmi ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Autoantibody; Biomarker; Cancer; MASCOT; Serum

Indexed keywords

AUTOANTIBODY; MEMBRANE PROTEIN; MITOCHONDRIAL PROTEIN; SIDEROFLEXIN 3; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY SCREENING; ARTICLE; BASEMENT MEMBRANE; CANCER SIZE; CELL CULTURE; CELL INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; EARLY CANCER; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SEROLOGY; SQUAMOUS CELL CARCINOMA; SQUAMOUS EPITHELIUM; TARGET CELL; TWO DIMENSIONAL ELECTROPHORESIS;

EID: 42449100881     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200780123     Document Type: Article

References (36)

1. Perkins, G. L., Slater, E. D., Sanders, G. K., Prichard, J. G., Serum tumor markers. Am. Fam. Physician 2003, 68, 1075-1082.
2. Kato, H., Torigoe, T., Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1977, 40, 1621-1628.
3. Fischbach, W., Meyer, T., Barthel, K., Squamous cell carcinoma antigen in the diagnosis and treatment follow-up of oral and facial squamous cell carcinoma. Cancer 1990, 65, 1321-1324.
4. Senekjian, E. K., Young, J. M., Weiser, P. A., Spencer, C. E. et al., An evaluation of squamous cell carcinoma antigen in patients with cervical squamous cell carcinoma. Am. J. Obstet. Gynecol. 1987, 157, 433-439.
5. Takahashi, Y., Shinoda, I., Takeuchi, T., Kuriyama, M. et al., Clinical assay of serum SCC-Ag in urothelial cancers. Int. J. Markers 1988, 3, 15-18.
6. Petrelli, N. J., Shaw, N., Bhargava, A., Daufeldt, J. et al., Squamous cell carcinoma antigen as a marker for squamous cell carcinoma of the anal canal. J. Clin. Oncol. 1988, 6, 782-783.
7. Kurokawa, H., Yamashita, Y., Tokudome, S., Kajiyama, M., Combination assay for tumor markers in oral squamous cell carcinoma. J. Oral Maxillofac. Surg. 1997, 55, 964-966.
8. Yen, T. C., Lin, W. Y., Kao, C. H., Cheng, K. Y. et al., A study of a new tumour marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin. Otolaryngol. Allied Sci. 1998, 23, 82-86.
9. Kerawala, C., Squamous cell carcinoma antigen. Oral Oncol. 2006, 42, 3-4.
10. Hamakawa, H., Fukizumi, M., Bao, Y., Sumida, T. et al., Genetic diagnosis of micrometastasis based on SCC antigen mRNA in cervical lymph nodes of head and neck cancer. Clin. Exp. Metastasis 1999, 17, 593-599.
11. Nagler, R., Bahar, G., Shpitzer, T., Feinmesser, R., Concomitant analysis of salivary tumor markers-a new diagnostic tool for oral cancer. Clin. Cancer Res. 2006, 12, 3979-3984.
12. Hirano, T., Kato, H., Present status of clinical proteomic analysis for the early detection and determination of therapeutic strategy in lung cancer. Ann. Thorac. Cardiovasc. Surg. 2006, 12, 4-9.
13. Brichory, F., Beer, D., Le Naour, F., Giordano, T. et al., Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res. 2001, 61, 7908-7912.
14. Kobayashi, R., A proteomics approach to find a new breast cancer-specific antigenic marker. Clin. Cancer Res. 2001, 7, 3325-3327.
15. Kageyama, S., Isono, T., Iwaki, H., Wakabayashi, Y. et al., Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin. Chem. 2004, 50, 857-866.
16. Alfonso, P., Nunez, A., Madoz-Gurpide, J., Lombardia, L. et al., Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresis. Proteomics 2005, 5, 2602-2611.
17. Brichory F. M., Misek, D. E., Yim, A. M., Krause, M. C. et al., An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc,. Natl. Acad. Sci. 2001, 98, 9824-9829.
18. Crawford, L. V., Pim, D. C., Bulbrook, R. D., Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer 1982, 30, 403-408.
19. Edis, C., Kahler, C., Klotz, W., Herold, M. et al., A comparison between α-fetoprotein and p53 antibodies in the diagnosis of hepatocellular carcinoma. Transplant. Proc. 1898, 30, 780-781.
20. Nesterova, M., Johnson, N., Cheadle, C., Cho-Chung, Y. S., Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim. Biophys. Acta 2006, 1762, 398-403.
21. Casiano, C. A., Mediavilla-Varela, M., Tan, E. M., Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol. Cell. Proteomics 2006, 5, 1745-1759.
22. Cui, J. W., Li, W. H., Wang, J., Li, A. L. et al., Proteomics-based identification of human acute leukemia antigens that induce humoral immune response, Mol. Cell. Proteomics 2005, 4, 1718-1724.
23. Abe, Y., Matsumoto, S., Kito, K., Ueda, N., Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells. J. Biol. Chem. 2000, 275, 21525-21531.
24. Fujibuchi, T., Abe, Y., Takeuchi, T., Ueda, N. et al., Expression and phosphorylation of TOPK during spermatogenesis. Dev. Growth Differ. 2005, 47, 837-644.
25. Brockmann, J. G., St. Nottberg, H., Glodny, B., Heinecke, A., Senninger, N. J., CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin. Cancer Res. 2000, 6, 4249-4259.
26. Kimura, Y., Fujieda, S., Takabayashi, T., Tanaka, T. et al., Conventional tumor markers are prognostic indicators in patients with head and neck squamous cell carcinoma. Cancer Lett. 2000, 155, 163-168.
27. Kulpa, J., Wójcik, E., Reinfuss, M., Kolodziejski, L., Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin. Chem. 2002, 48, 1931-1937.
28. Yamamoto, K., Oka, M., Hayashi, H., Tangoku, A. et al., CVFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer 1997, 79, 1647-1655.
29. Zhong, L. P., Zhu, H. G., Zhang, C. P., Chen, W. T., Zhang, Z. Y., Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma. Int. J. Oral Maxillofac. Surg. 2007, 36, 230-234.
30. Bachelot, T., Ratel, D., Menetrier-Caux, C., Wion, D. et al., Autoantibodies to endostatin in patients with breast cancer: Correlation to endostatin levels and clinical outcome. Br. J. Cancer 2006. 94, 1066-1070.
31. Lechpammer, M., Lukac, J., Lechpammer, S., Kovacevic, D. et al., Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int. J. Colorectal Dis. 2004, 19, 114-120.
32. Lockhart, P. J., Holtom, B., Lincoln, S., Hussey, J. et al., The human sideroflexin 5 (SFXN5) gene: Sequence, expression analysis and exclusion as a candidate for PARK3. Gene 2002, 285, 229-237.
33. Roy, C. N., Andrews, N. C., Recent advances in disorders of iron metabolism: Mutations, mechanisms and modifiers. Hum. Mol. Genet. 2001, 10, 2181-2186.
34. Zheng, H., Ji, C., Zou, X., Wu, M. et al., Molecular cloning and characterization of a novel human putative transmembrane protein homologous to mouse sideroflexin associated with sideroblastic anemia. DNA Seq. 2003, 14, 369-373.
35. Richardson, D. R., Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer. Curr. Med. Chem. 2005, 12, 2711-2729.
36. Ke, Q., Costa, M., Hypoxia-inducible Factor-1 (HIF-1). Mol. Pharmacol. 2006, 70, 1460-1480.